阿福他酶α价格一览

Aphthase α is an enzyme replacement therapy drug. The original drug is produced by Strensiq Pharmaceuticals in the United States and is branded Strensiq. The price of this drug is relatively high in the international market, with the price of 18mg/0.45mL/box being approximately US$13,205. There are currently no generic drugs on the market.

Prices of original and generic drugs for aftase alfa

The original drug Strensiq was developed by Ruisong Pharmaceuticals (now a subsidiary of AstraZeneca) in the United States. It is currently the only enzyme replacement therapy approved in the world for the treatment of hypophosphatasia.

Original drug price

There are many specifications of aftase alpha, and the prices of different specifications are also different. It is currently understood that the price of 18mg/0.45mL/box of aftase α is approximately US$13,205. It is relatively expensive and requires long-term use by patients, which imposes a heavy financial burden. There are currently no generic drugs on the market.

Price of generic drugs

Currently, no generic drug of aftase α has been approved for marketing worldwide, and the price of generic drugs cannot be known.

The high cost of aftase alpha limits its widespread use worldwide, and patients are looking forward to more economical alternative treatments in the future.

Domestic marketing status of aftase α

As of June 2025, aftase α has not yet been approved for marketing in mainland China. The approval process for rare disease drugs in China is relatively long and must meet strict regulatory requirements.

The marketing application for aftase α may involve multiple evaluations such as clinical trial data and production quality inspection. In addition, pharmacoeconomic evaluation is also a key factor affecting its entry into the medical insurance catalog.

With the improvement of the domestic rare disease diagnosis and treatment system in the future, aftase α is expected to accelerate the approval process and benefit more Chinese patients.

The efficacy of afotalase α

As the world’s first enzyme replacement therapy for hypophosphatasia, the clinical efficacy of afotalase α has been confirmed by multiple studies. The drug improves bone mineralization and metabolic abnormalities by supplementing the missing alkaline phosphatase in patients.

Significantly improve survival rate

Clinical data show that the 1-year survival rate of perinatal/infancy patients treated with aftase α is higher, and the 5-year survival rate is higher than that of the control group, with significant differences in efficacy.

Improve bone and respiratory function

This drug can reverse insufficient bone mineralization, promote an increase in bone density, and reduce the risk of fractures. At the same time, it can improve the symptoms of respiratory muscle weakness and reduce the incidence of respiratory failure in infants and young children. Long-term treatment can also help children achieve substantial cure for rickets.

Afotalase alfa brings a revolutionary treatment option to patients with hypophosphatasia, and its efficacy has changed the natural history of the disease.